Medizinische Hochschule Hannover;The Governors of the University of Alberta
发明人:
Abdolamir Landi,Michael Houghton,D. Lorne Tyrrell,Tim Lankisch,Tobias Weismueller,Michael Manns
申请号：
US15922012
公开号：
US20180209992A1
申请日:
2018.03.15
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.
